biote Corp.

Haymaker Acquisition Corp. III (Nasdaq: HYAC), sponsored by Haymaker Partners, completed its initial public offering in 2021 targeting the healthcare and consumer wellness sector. In December 2021, the blank-check company filed an 8-K with the SEC disclosing details related to its proposed business combination with biote Corp., a Southlake, Texas-based company specializing in bioidentical hormone replacement therapy and hormone optimization training for healthcare practitioners. The transaction advanced the merger process that would bring biote Corp. to public markets, with the combined company subsequently trading on Nasdaq under the ticker BTMD following closing in 2022. Sign up at SpacDesk for full filing histories, deal timelines, and comprehensive SPAC analytics.